Integumen’s Labskin to test Covid-19 transmission risk in products
Francesca Morgan
RNS Newswires
10:26, 3rd June 2020

Integumen (AIM:SKIN) FOLLOW said its subsidiary, Labskin, has partnered with the University of Aberdeen to test anti-viral skin and dental products that could mitigate the transmission risk of coronavirus. 
 
Scientists will use Labskin’s cloned human skin coated with the SARS-CoV-2 virus as part of the research which will take place in a Category 3 lab at the University of Aberdeen. 
 
Work will be carried out assessing the transmissibility impact of the virus to and from human skin as well as the ability of the virus to remain infective while on the skin surface. 
 
Shares in Integumen were trading 9.97% higher at 1.875p on Wednesday morning. 

 The aim of the study is to quantify the efficacy of mouthwash and dental care products as well as soap washing and hand sanitisers. 
 
“It is important to find products that can help to mitigate the risk of infection, particularly, in professional settings,” said Gerard Brandon, Chief Executive of Integumen. 
 
He said the group would study the effects of a variety of products and ingredients “without exposing human volunteers to dangerous and challenging clinical trial contamination risk.” 
 
He added, “The more knowledge we have about SARS-CoV-2 - how it spreads, and more importantly, how to contain that spread - the better equipped to fight this virus we will be." 
 
The group said results from the trial are expected in the next six weeks. 
 
Follow News & Updates from Integumen here: FOLLOW

 

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist